platinol-aq- cisplatin injection, solution
corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol-aq (cisplatin injection) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol-aq and cyclophosphamide. platinol-aq, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol-aq therapy. platinol-aq is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol-aq is contraindicated in patients with preexisting renal impairme
platinol- cisplatin injection, powder, lyophilized, for solution
corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol (cisplatin for injection, usp) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol and cyclophosphamide. platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol therapy. platinol is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol is contraindicated in patients with preexisting renal impairment. plati
cytosar powder lyophilized for solution for injection
corden pharma latina s.p.a - cytarabine - powder lyophilized for solution for injection - 100mg
cytosar powder lyophilized for solution for injection
corden pharma latina s.p.a - cytarabine - powder lyophilized for solution for injection - 500mg
cytosar powder lyophilized for solution for injection
corden pharma latina s.p.a - cytarabine - powder lyophilized for solution for injection - 500mg
cytosar powder lyophilized for solution for injection
corden pharma latina s.p.a - cytarabine - powder lyophilized for solution for injection - 100mg
farmorubicin rapid dissolution powder lyophilized for solution for infusion
corden pharma latina s.p.a - epirubicin (epirubicin hydrochloride) - powder lyophilized for solution for infusion - 10mg
farmorubicin rapid dissolution powder lyophilized for solution for infusion
corden pharma latina s.p.a - epirubicin (epirubicin hydrochloride) - powder lyophilized for solution for infusion - 50mg
maxipime injection 2 g
bristol-myers squibb (singapore) pte. ltd. - cefepime 2hcl monohydrate eqv cefepime - injection - 2 g/vial
taxol for injection concentrate 6 mg/ml
bristol-myers squibb (singapore) pte. ltd. - paclitaxel - injection - 6 mg/ml